Literature DB >> 25802017

Associations of Trimethylamine N-Oxide With Nutritional and Inflammatory Biomarkers and Cardiovascular Outcomes in Patients New to Dialysis.

George A Kaysen1, Kirsten L Johansen2, Glenn M Chertow3, Lorien S Dalrymple4, John Kornak5, Barbara Grimes5, Tjien Dwyer4, Alexander W Chassy6, Oliver Fiehn6.   

Abstract

OBJECTIVES: Trimethylamine N-oxide (TMAO) is a product of metabolism of phosphatidylcholine (lecithin) and carnitine by the intestinal microbiome. Elevated serum concentrations of TMAO have been linked to adverse cardiovascular outcomes in the general population. We examined correlates of serum TMAO and the relations among serum TMAO concentrations, all-cause mortality, and cardiovascular mortality and hospitalizations in a nationally derived cohort of patients new to hemodialysis (HD).
METHODS: We quantified serum TMAO by liquid chromatography and online tandem mass spectrometry and assessed nutritional and cardiovascular risk factors in 235 patients receiving HD and measured TMAO in pooled serum from healthy controls. We analyzed time to death and time to cardiovascular death or hospitalization using Cox proportional hazards regression.
RESULTS: Serum TMAO concentrations of patients undergoing HD (median, 43 μM/L; 25th-75th percentile, 28-67 μM/L) were elevated compared with those with normal or near-normal kidney function (1.41 ± 0.49 μM/L). TMAO was directly correlated with serum albumin (Spearman rank correlation, 0.24; 95% CI, 0.12-0.35; P <.001), prealbumin (Spearman rank correlation, 0.19; 95% CI, 0.07-0.31; P = .003), and creatinine (Spearman rank correlation, 0.21; 95% CI, 0.08-0.33; P = .002) and inversely correlated with log C-reactive protein (Spearman rank correlation, -0.18; 95% CI, -0.30 to -0.06; P = .005). Higher serum concentrations of TMAO were not significantly associated with time to death (Spearman rank correlation, 0.84; CI, 0.65-1.09; P = .19) or time to cardiovascular hospitalization or cardiovascular death (Spearman rank correlation, 0.88; CI, 0.57-1.35; P = .55).
CONCLUSIONS: Serum TMAO concentrations were markedly elevated and correlated directly with biochemical markers of nutritional status and inversely with markers of inflammation in patients receiving HD. There was no significant association between serum TMAO concentrations and all-cause mortality, cardiovascular death, or hospitalizations. In patients receiving dialysis-in contrast with the general population-adverse vascular effects of TMAO may be counterbalanced by associations with nutritional or inflammatory status.
Copyright © 2015 National Kidney Foundation, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25802017      PMCID: PMC4469547          DOI: 10.1053/j.jrn.2015.02.006

Source DB:  PubMed          Journal:  J Ren Nutr        ISSN: 1051-2276            Impact factor:   3.655


  28 in total

1.  In vivo variability of TMA oxidation is partially mediated by polymorphisms of the FMO3 gene.

Authors:  D M Lambert; O A Mamer; B R Akerman; L Choinière; D Gaudet; P Hamet; E P Treacy
Journal:  Mol Genet Metab       Date:  2001-07       Impact factor: 4.797

2.  Prealbumin is associated with visceral fat mass in patients receiving hemodialysis.

Authors:  Alessio Molfino; Steven B Heymsfield; Fansan Zhu; Peter Kotanko; Nathan W Levin; Tjien Dwyer; George A Kaysen
Journal:  J Ren Nutr       Date:  2013-04-24       Impact factor: 3.655

3.  Changes in plasma lecithin: cholesterol acyltransferase activity, HDL(2), HDL(3) amounts and compositions in patients with chronic renal failure after different times of hemodialysis.

Authors:  Khedidja Mekki; Malika Bouchenak; Myriem Lamri; Mustapha Remaoun; Jacques Belleville
Journal:  Atherosclerosis       Date:  2002-06       Impact factor: 5.162

4.  Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients.

Authors:  G A Kaysen; G M Chertow; R Adhikarla; B Young; C Ronco; N W Levin
Journal:  Kidney Int       Date:  2001-07       Impact factor: 10.612

5.  Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease.

Authors:  W H Wilson Tang; Zeneng Wang; David J Kennedy; Yuping Wu; Jennifer A Buffa; Brendan Agatisa-Boyle; Xinmin S Li; Bruce S Levison; Stanley L Hazen
Journal:  Circ Res       Date:  2014-11-05       Impact factor: 17.367

Review 6.  Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review.

Authors:  Jean-Marc Hurot; Michel Cucherat; Margaret Haugh; Denis Fouque
Journal:  J Am Soc Nephrol       Date:  2002-03       Impact factor: 10.121

Review 7.  The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease.

Authors:  Hans-Joachim Anders; Kirstin Andersen; Bärbel Stecher
Journal:  Kidney Int       Date:  2013-01-16       Impact factor: 10.612

8.  Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients.

Authors:  George A Kaysen; Tom Greene; John T Daugirdas; Paul L Kimmel; Gerald W Schulman; Robert D Toto; Nathan W Levin; Guofen Yan
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

Review 9.  L-Carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: a systematic review and meta-analysis.

Authors:  Yizhi Chen; Manuela Abbate; Li Tang; Guangyan Cai; Zhixiang Gong; Ribao Wei; Jianhui Zhou; Xiangmei Chen
Journal:  Am J Clin Nutr       Date:  2013-12-24       Impact factor: 7.045

10.  Effect of chronic renal failure on the hepatic, intestinal, and renal expression of bile acid transporters.

Authors:  Zhibo Gai; Lei Chu; Christian Hiller; Denis Arsenijevic; Carlos A Penno; Jean-Pierre Montani; Alex Odermatt; Gerd A Kullak-Ublick
Journal:  Am J Physiol Renal Physiol       Date:  2013-11-06
View more
  64 in total

1.  Trimethylamine N-Oxide as a Novel Therapeutic Target in CKD.

Authors:  W H Wilson Tang
Journal:  J Am Soc Nephrol       Date:  2015-07-30       Impact factor: 10.121

2.  Trimethylamine N-Oxide and Cardiovascular Events in Hemodialysis Patients.

Authors:  Tariq Shafi; Neil R Powe; Timothy W Meyer; Seungyoung Hwang; Xin Hai; Michal L Melamed; Tanushree Banerjee; Josef Coresh; Thomas H Hostetter
Journal:  J Am Soc Nephrol       Date:  2016-07-19       Impact factor: 10.121

Review 3.  Hemodialysis-induced cardiovascular disease.

Authors:  Shadi Ahmadmehrabi; W H Wilson Tang
Journal:  Semin Dial       Date:  2018-04-06       Impact factor: 3.455

4.  Assessing Clinical Relevance of Uremic Toxins.

Authors:  Jennifer E Flythe; Thomas H Hostetter
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-21       Impact factor: 8.237

Review 5.  Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies.

Authors:  Wei Pan; Yongbo Kang
Journal:  Int Urol Nephrol       Date:  2017-08-28       Impact factor: 2.370

Review 6.  Short chain fatty acids and methylamines produced by gut microbiota as mediators and markers in the circulatory system.

Authors:  Maksymilian Onyszkiewicz; Kinga Jaworska; Marcin Ufnal
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-16

Review 7.  An overview of renal metabolomics.

Authors:  Sahir Kalim; Eugene P Rhee
Journal:  Kidney Int       Date:  2016-09-28       Impact factor: 10.612

Review 8.  The gut microbiome, diet, and links to cardiometabolic and chronic disorders.

Authors:  Judith Aron-Wisnewsky; Karine Clément
Journal:  Nat Rev Nephrol       Date:  2015-11-30       Impact factor: 28.314

Review 9.  Microbiome, trimethylamine N-oxide, and cardiometabolic disease.

Authors:  W H Wilson Tang; Stanley L Hazen
Journal:  Transl Res       Date:  2016-07-18       Impact factor: 7.012

Review 10.  Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease.

Authors:  Daniel Y Li; W H Wilson Tang
Journal:  Semin Nephrol       Date:  2018-03       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.